A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2011
11/01/2011	CA2490277C Use of vasopeptidase inhibitors in the treatment of nephropathy
11/01/2011	CA2490254C Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
11/01/2011	CA2483750C Biologically active compounds for the modification of bodily odours
11/01/2011	CA2481261C Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds
11/01/2011	CA2479012C Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
11/01/2011	CA2476586C Sulfonyl-derivatives as novel inhibitors of histone deacetylase
11/01/2011	CA2475224C Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
11/01/2011	CA2473591C 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
11/01/2011	CA2473461C Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
11/01/2011	CA2468826C Benzazole derivatives for the treatment of scleroderma
11/01/2011	CA2458534C Phenethanolamine derivatives for treatment of respiratory diseases
11/01/2011	CA2446193C 1,4-disubstituted benzo-fused cycloalkyl urea compounds
11/01/2011	CA2434526C Methods of administering epothilone analogs for the treatment of cancer
11/01/2011	CA2409741C Tnf-.alpha. production inhibitors
11/01/2011	CA2402247C Biodegradable immunomodulatory formulations and methods for use thereof
11/01/2011	CA2375910C Tanacetum parthenium extract
11/01/2011	CA2320073C Method of controlling proliferation and differentiation of stem and progenitor cells
11/01/2011	CA2311318C Mitochondrially targeted antioxidants
11/01/2011	CA2275890C Stable liquid interferon formulations
11/01/2011	CA2176942C Bmp-12, bmp-13 and tendon-inducing compositions thereof
10/2011
10/27/2011	WO2011132712A1 Novel hydroxamic acid derivative
10/27/2011	WO2011132672A1 Method for stabilizing functional nucleic acids
10/27/2011	WO2011132633A1 Substituted 5-hydroxypyrimidine-4-carboxamide compound
10/27/2011	WO2011132191A1 Casein peptide for use in the treatment of uterine infections
10/27/2011	WO2011131661A1 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
10/27/2011	WO2011131026A1 Furo[3, 2-g]chromene compounds and uses thereof
10/27/2011	US20110265198 Genome editing of a Rosa locus using nucleases
10/27/2011	US20110263708 Over-production of dihomo linolenic acid by a mutant strain of parietochloris incisa
10/27/2011	US20110263706 Method for enhancing the dna repair process, treating disorders associated with the dna repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering pruified quinic acid and/or carboxy alkyl ester
10/27/2011	US20110263684 Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene
10/27/2011	US20110263638 Therapeutic agent for glaucoma comprising rho kinase inhibitor and ß- blocker
10/27/2011	US20110263619 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
10/27/2011	US20110263609 Methods of Identifying and Treating Individuals Exhibiting NUP214-ABL1 Positive T-Cell Malignancies with Protein Tyrosine Kinase Inhibitors and Combinations Thereof
10/27/2011	US20110263584 Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1
10/27/2011	US20110263577 Novel oxadiazolyl-diazabicyclononane derivatives and their medical use
10/27/2011	US20110263568 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
10/27/2011	US20110263532 Halofuginone analogs for inhibition of trna synthetases and uses thereof
10/27/2011	US20110263519 Regulators of the hedgehog pathway, compositions and uses related thereto
10/27/2011	US20110263515 Capture agents and related compositions, methods and systems
10/27/2011	US20110263510 Methods of Inhibiting Cell Death or Inflammation in a Mammal
10/27/2011	US20110263481 Pharmaceutical Composition of Lyophilized Formulation and Preparation Method of the Same
10/27/2011	US20110262542 Controlled Delivery of Tetracycline Compounds and Tetracycline Derivatives
10/27/2011	US20110262536 Method to authenticate genuine tablets manufactured by compressing powder
10/27/2011	US20110262503 Flowable Wound Matrix and its Preparation and Use
10/27/2011	US20110262501 Osteoblast Stimulating Orthopedic Implant
10/27/2011	US20110262429 Human timp-1 antibodies
10/27/2011	US20110262419 Specifically targeted catalytic antagonists and uses thereof
10/27/2011	US20110262399 Porphobilinogen deaminase gene therapy
10/27/2011	US20110262385 Use of interleukin-22 in the treatment of fatty liver disease
10/27/2011	US20110262366 Compounds for targeting endothelial cells, compositions containing the same and methods for their use
10/27/2011	US20110262359 Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
10/27/2011	US20110262358 Molecular marker for cancer stem cell
10/27/2011	US20110262352 Aryl piperazine and their use as alpha2c antagonists
10/27/2011	US20110262351 Fluorescent silica nanoparticle with radioactive tag and the detecting method of pet and fluorescent dual imaging using thereof
10/27/2011	US20110262347 Methods and compositions for enhanced delivery of compounds
10/26/2011	EP2380892A1 Imidazothiazole derivative having proline ring structure
10/26/2011	EP2380881A1 Novel bicyclic heterocyclic compound
10/26/2011	EP2181985B1 Antiviral Agent
10/26/2011	EP2083267B1 Diagnosis and treatment of autism using cd38
10/26/2011	EP1916245B1 Indole derivative having pgd2 receptor antagonist activity
10/26/2011	EP1864994B1 Par-2 agonist
10/26/2011	EP1587477B1 Odorless formulation for treating mucosal discontinuities
10/26/2011	EP1518855B1 Diaminopyrimidinecarboxa mide derivative
10/26/2011	EP1438378B1 Cholesterol lowering structured lipids with omega 6 pufa
10/26/2011	EP1429729B1 Combination dosage form containing a cholesterol -lowering agent , an inhibitor of the renin-angiotensin, and aspirin
10/26/2011	EP1425010B1 Substituted indoles and their use as integrin antagonists
10/26/2011	CN102227430A Modulators of cystic fibrosis transmembrane conductance regulator
10/26/2011	CN102227409A Pyridine-3-carboxyamide derivative
10/26/2011	CN102227220A Hsp90 inhibitors for therapeutic treatment
10/26/2011	CN102225194A Use of Bv8 and/or EG-VEGF to promote hematopoiesis
10/26/2011	CN102225163A Traditional Chinese medicine composition for treating heatstroke and preparation method thereof
10/26/2011	CN101757564B Traditional Chinese medicine composition for treating liver depression and qi stagnation
10/26/2011	CN101305837B Cigarette with function of invigorating vital function
10/26/2011	CN101048166B Abnormal protein removing composition
10/25/2011	US8044207 Pyridinoylpiperidines as 5-HT1F agonists
10/25/2011	US8044206 Nitrogen—containing heterocyclic derivatives having 2,6-disubstituted styryl
10/25/2011	US8044182 Adiponectin and uses thereof
10/25/2011	US8044103 Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
10/25/2011	US8044070 Heteroaryloxy nitrogenous saturated heterocyclic derivative
10/25/2011	US8044042 Thienotriazolodiazepine compound and medicinal use thereof
10/25/2011	US8044040 e.g. 3-{3-Cyano-6-[(2,2-dimethyl-propyl)-methyl-amino]-5-fluoro-pyridin-2-ylamino}-N-methoxy-4-methyl-benzamide; via p38 kinase inhibition; (anilino)(halo)pyrimidine or (anilino)(amino)pyrimidine derivatives; rheumatoid arthritis, psoriasis, Crohn's Disease, osteoarthritis or osteoporosis
10/25/2011	US8043855 vector contains an adenoviral genome from which the open reading frames E1 and/or E3 have been deleted, but retains enough sequence to make it able to replicate in vitro; also contains a DNA sequence regulated by promoters that encode for fibrosis treatment proteins
10/25/2011	US8043831 Therapeutic agents comprising pro-apoptotic proteins
10/25/2011	US8043806 Method of diagnosing an RTK-hyperfunction induced disorder
10/25/2011	US8043628 biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer comprising hydroxyaliphatic carboxylic acids, and polysaccharides
10/25/2011	US8043612 Infection and treatment of neoplasms with vesicular stomatitis virus
10/25/2011	CA2486380C N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors
10/25/2011	CA2484020C Re-epithelializing pharmaceutical compositions comprising xanthan gum
10/25/2011	CA2460834C Matrix metalloproteinase inhibitor
10/25/2011	CA2454658C Methods for treating joint inflammation, pain, and loss of mobility
10/25/2011	CA2437983C Transporters comprising spaced arginine moieties
10/25/2011	CA2437866C Novel clock gene bmal2
10/25/2011	CA2366277C Grb7 family proteins and the insulin receptor for screening new medications
10/25/2011	CA2341568C Stabilized pharmaceutical composition in lyophilized form
10/25/2011	CA2302228C Sterilized 5-aminolevulinic acid
10/20/2011	WO2011129781A1 Diabetic foot processor system
10/20/2011	WO2011129428A1 Cosmetic composition containing plum extract
10/20/2011	WO2011129427A1 Diagnostic agent and therapeutic agent for cancer
10/20/2011	WO2011129424A1 Pharmaceutical agent for prevention and/or treatment of htlv-1-associated myelopathy
10/20/2011	WO2011129399A1 Srebp inhibitor

1 ... 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 ... 1564